Valuation: Palisade Bio, Inc.

Market Cap 350M 300M 281M 257M 485M 33.39B 490M 3.32B 1.29B 16.85B 1.32B 1.29B 55.8B P/E 2026 *
-8.93x
P/E 2027 * -7.28x
Enterprise Value 253M 216M 203M 185M 350M 24.08B 353M 2.39B 931M 12.15B 948M 928M 40.23B EV / Sales 2026 *
707x
EV / Sales 2027 * -
Free-Float
98.26%
Yield 2026 *
-
Yield 2027 * -
1 day+2.99%
1 week-3.72%
Current month+9.23%
1 month+6.15%
3 months+6.15%
6 months+15.64%
Current year-11.91%
1 week 1.98
Extreme 1.98
2.19
1 month 1.86
Extreme 1.855
2.22
Current year 1.45
Extreme 1.45
2.86
1 year 0.53
Extreme 0.53
2.86
3 years 0.53
Extreme 0.53
28.95
5 years 0.53
Extreme 0.53
2,400
10 years 0.53
Extreme 0.53
8,182.5
Manager TitleAgeSince
Chief Executive Officer 68 2022-10-09
President 48 -
Chief Tech/Sci/R&D Officer - 2025-10-27
Director TitleAgeSince
Chairman 67 2024-02-13
Director/Board Member 55 2018-12-31
Director/Board Member 68 2023-02-01
Date Insider Type Main position Quantity % Market Cap.
8/19/26 Don

Chief Executive Officer

-176,800 0.1066%
7/9/26 Buy

Director

25,000 0.0151%
7/7/26 Buy

Director

30,000 0.0181%
Change 5-day change 1-year change 3-year change Capi.($)
+2.99%-3.72%+174.54%-77.74% 350M
+1.02%+4.84%+4.80%+24.36% 51.21B
-0.09%-0.29%+471.14%+564.30% 45.35B
-0.32%+7.54%+35.72%+20.37% 42.84B
+1.18%+3.82%+19.99%+89.24% 42.29B
-2.27%-5.67%+14.55%+50.34% 32.15B
-0.96%+2.84%+32.44%+142.88% 17.31B
+0.41%+2.26% - - 16.55B
+1.12%+5.83%+8.37%+32.33% 14.84B
-0.31%+3.84%+83.91%+49.85% 14.25B
Average +0.30%+2.56%+93.94%+99.55% 27.71B
Weighted average by Cap. +0.10%+2.89%+101.30%+140.99%

Financials

2026 *2027 *
Net sales 357K 306K 287K 262K 494K 34.05M 499K 3.38M 1.32M 17.18M 1.34M 1.31M 56.89M -
Net income -47.86M -41.01M -38.43M -35.1M -66.25M -4.56B -66.9M -453M -176M -2.3B -180M -176M -7.62B -63.05M -54.03M -50.62M -46.24M -87.27M -6.01B -88.13M -597M -232M -3.03B -237M -232M -10.04B
Net Debt -97.7M -83.72M -78.45M -71.66M -135M -9.31B -137M -925M -360M -4.7B -367M -359M -15.56B -335M -287M -269M -245M -463M -31.91B -468M -3.17B -1.23B -16.1B -1.26B -1.23B -53.31B
Logo Palisade Bio, Inc.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
Employees
-
Date Price Change Volume
26-08-25 US$2.070 +2.99% 2,067,873
26-08-24 US$2.010 -4.29% 1,618,511
26-08-21 US$2.100 +1.94% 1,070,498
26-08-20 US$2.060 -4.63% 1,324,937
26-08-19 US$2.160 +5.88% 2,290,012
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.070USD
Average target price
10.22USD
Spread / Average Target
+393.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PALI Stock